<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172872</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1301</org_study_id>
    <secondary_id>2014-001486-27</secondary_id>
    <nct_id>NCT02172872</nct_id>
  </id_info>
  <brief_title>&quot;InDACtion&quot; vs &quot;3+7&quot; Induction in AML</brief_title>
  <official_title>10-day Decitabine Versus Conventional Chemotherapy (&quot;3+7&quot;) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older patients with acute myeloid leukemia (AML) have a small (&lt; 10%) chance of long-term
      survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the
      survival has not been improved during the last decades.

      The purpose of this study is to determine whether frontline therapy with a 10-day decitabine
      schedule provides a better survival than standard intensive combination chemotherapy in
      elderly AML patients (&gt;= 60 years).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The overall survival (OS) of older AML patients has not been improved during the last
           decades with intensive chemotherapy based on cytarabine combined with an anthracycline
           (&quot;3+7&quot;).

        -  Next generation sequencing technology reveals that mutations in genes involved in
           epigenetics are frequently mutated in AML (e.g. DNMT3a), suggesting an important role of
           epigenetics in the pathophysiology of AML. Decitabine (given in a 5-day schedule) has
           been shown to be superior to low-dose Ara-C.

        -  A retrospective analysis revealed that epigenetic therapy (either azacitidine or
           decitabine) is associated with similar survival rates as intensive chemotherapy in older
           patients (n=671) with newly diagnosed AML.

        -  The recently published encouraging phase 2 data with the 10-day decitabine schedule
           suggests that decitabine results in similar CR rates compared with intensive
           chemotherapy. Allogeneic transplantation (alloHCT) also offers the opportunity for cure
           among older AML patients, therefore treatment strategies should aim to allograft older
           AML patients.

        -  Decitabine treatment can lead to very interesting cure rates when used as &quot;bridging&quot; to
           allografting.

      Based on the data summarized above, we hypothesize that decitabine at a daily dose of 20
      mg/m² starting with the 10-day schedule followed by an alloHCT or by continuation of 5-days
      decitabine cycles is superior to conventional intensive chemotherapy in older AML patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4.9 years from first patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs)</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>The events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) from randomization to the date of either first progression, first relapse or death, whichever occurs first</measure>
    <time_frame>4.9 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantation feasibility</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>Percentage of patients transplanted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome post-transplantation</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>PFS, incidence of relapse or progression, and incidence of non-relapse or progression related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics impact of each treatment arm</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>At the end of each cycle, duration of hospitalization and number of visits (planned or related to event), number of transfusions, growth factor support and intravenous anti-infective are collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL) questionnaires</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>EORTC Quality of Life Questionnaire (QLQ-C30) Elderly module (ELD14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of baseline physical and functional conditions on treatment outcome using geriatric assessment tools</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>Short physical performance battery (SPPB) and activities of daily living (ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response (CR/CRi) rate</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>All patients who reached complete response (CR) or complete response with incomplete marrow recovery (CRi) after the administration of protocol treatment (&quot;3+7&quot; or decitabine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall CR/CRi rate</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>All patients who reached CR or CRi, after administration of the protocol treatment (&quot;3+7&quot; or decitabine) or following another salvage/new treatment for AML (other than transplant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS) from CR or CRi</measure>
    <time_frame>4.9 years from first patient in</time_frame>
    <description>The time between the date of CR or CRi and the date of first relapse or death (whatever the cause), whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>standard combination chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard combination chemotherapy</intervention_name>
    <description>Cycle 1
daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 2
daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 3 (mini-ICE)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days
Cycle 4 (mini-ICE) (optional)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days</description>
    <arm_group_label>standard combination chemotherapy</arm_group_label>
    <other_name>&quot;3+7&quot; induction chemotherapy</other_name>
    <other_name>Intensive combined chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 2
if bone marrow (BM) blasts &lt; 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts &gt;= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 3
if BM blasts &lt; 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts &gt;= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days
Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days
Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.</description>
    <arm_group_label>decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age ≥ 60 years

          2. WHO Performance status ≤ 2

          3. Eligible for standard intensive chemotherapy

          4. Newly diagnosed AML cytopathologically confirmed to the WHO classification (up to 2
             months prior to randomization)

          5. De novo or secondary AML is allowed

          6. White blood cell (WBC) count is ≤ 30x10E9/L (measured within 72 hours prior to
             randomization).

          7. Laboratory assessments (measured prior to randomization):

               1. serum glutamate oxaloacetate transaminase (SGOT / ASAT) and serum glutamate
                  pyruvate transaminase (SGPT / ALAT) &lt; 2.5 x the upper limit of normal range
                  unless considered AML-related

               2. Total serum bilirubin &lt; 2.5 x the upper limit of normal range unless considered
                  AML-related or due to Gilbert's syndrome

               3. Serum creatinine &lt; 2.5 x the upper limit of normal range unless considered
                  AML-related

          8. Patients of reproductive potential should use adequate birth control measures, as
             defined by investigator, during the study treatment period and for at least 3 months
             after the last study treatment.

          9. Before patient registration/randomization, written informed consent must be given
             according to the International Conference of Harmonization good clinical practice (ICH
             GCP) and national/local regulations

        Exclusion criteria:

          1. Presence of acute promyelocytic leukemia (APL, i.e. AML-M3 with t(15;17)(q22;q12);
             promyelocytic leukemia - retinoic acid receptor-alpha (PML-RARA) fusion gene and
             cytogenetic variants)

          2. Presence of blast crisis of chronic myeloid leukemia

          3. Presence of active central nervous system (CNS) leukemia

          4. Patients did not receive any prior treatment for AML (relapsed AML is not allowed),
             such as any antileukemic therapy including investigational agents and hypomethylating
             agents (decitabine, 5-azacytidine). Treatment with hydroxyurea (HU) is allowed to
             control the leukocytosis if given preferably for less than 5 days and is stopped at
             least two days prior to the start of any of the protocol regimens

          5. Patients received any prior treatment for myelodysplastic syndrome (MDS) or
             myeloproliferative neoplasms (MPN) with:

               1. hypomethylating agents (decitabine, 5-azacytidine), OR

               2. with intensive chemotherapy or transplantation within the last three years

               3. NOTE: The following treatments for previous MDS or MPN are allowed (up to one
                  month before inclusion):

                    -  Growth factors, thrombomimetics, immunosuppression (cyclosporin A, steroids,
                       antithymocyte globulin etc.), chelation, interferons, anagrelide

                    -  Lenalidomide, low-dose chemotherapy (low-dose melphalan, HU, low-dose
                       cytarabine etc.), tyrosine-kinase inhibitors, histone deacetylase inhibitors
                       (e.g. valproic acid, panobinostat etc.), mammalian target of rapamycin
                       (mTOR) inhibitors, other experimental treatment that is not based on
                       inhibition of deoxyribonucleic acid (DNA) methyltransferase

          6. Presence of concomitant severe cardiovascular disease which would make intensive
             chemotherapy impossible, i.e. uncontrolled arrhythmias requiring chronic treatment,
             congestive heart failure or symptomatic ischemic heart disease, reduced left
             ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram

          7. Presence of any malignancy (except basal and squamous cell carcinoma of the skin) for
             which the patient received systemic anticancer treatment within 6 months prior to
             randomization NOTE: Diagnosis of any previous or concomitant malignancy is thus not an
             exclusion criterion.

          8. Presence of active uncontrolled infection

          9. Presence of any psychological, familial, sociological or geographical condition in the
             opinion of the investigator potentially hampering compliance with the study protocol
             and follow-up schedule; those conditions should be discussed with the patient before
             registration in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Luebbert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum Freiburg, Freiburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerwin G Huls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG, Groningen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre W Wijermans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HagaZiekenhuis, the Hague, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kin Jip Cheung, PhD</last_name>
    <phone>+32 2 774 16 07</phone>
    <email>kin-jip.cheung@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zwi Berneman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne De Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Verviers</name>
      <address>
        <city>Verviers</city>
        <state>Liège</state>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gaetan Vanstraelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.Z. St. Jan</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sebastian Wittnebel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Hôpital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard De Prijck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR De La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beata Hodossy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Specialized Hospital for Active Treatment of Haematological Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simec N. Gredelj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Radovan Vrhovac, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Chantepie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain Chantepie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ollivier Legrand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen AÖR - Medizinische Fakultät der RWTH</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martina Crysandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjoern Hackanson</last_name>
    </contact>
    <investigator>
      <last_name>Bjoern Hackanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Schoendube</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Schoendube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken - Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Fuhrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Germing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Noppeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Lübbert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetklinikum Halle - Martin Luther Universitaet - Universitaetsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haifa K Al-Ali</last_name>
    </contact>
    <investigator>
      <last_name>Haifa K Al-Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dietger Niederwieser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Der Phillips - Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Neubauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum St. Josefklinik</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitaet Rostock - Medizinische Fakultaet</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Junghanss, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Junghanss, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte Kragl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria - Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Attilio Olivieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicole Cantore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Bari - Policlinico</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giorgina Specchia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Martinelli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A. Pugliese</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Molica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Foggia</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana F Capalbo</last_name>
    </contact>
    <investigator>
      <last_name>Silvana F Capalbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Luppi, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Luppi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amedeo Avogadro University of Eastern Piedmont-Ospedale Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gianluca Gaidano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico P. Giaccone - Universita Di Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Enza Mitra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Maddalena S.P.A.</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Visani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Visani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna - Ospedale Santa Maria dell Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eliana Zuffa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Di S. Maria Nuova</name>
      <address>
        <city>Reggio nell'Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Imovilli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annalisa Imovilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna - Ospedale Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Maria Mianulli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. San Giovanni - Addolorata</name>
      <address>
        <city>Roma</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Chierichini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Roma La Sapienza - Ospedale Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agustino Tafuri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedallera Universitaria - Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Venditti, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Adriano Venditti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Regina Elena / Instituti Fisioterapici Ospitalieri</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Mengarelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Mengarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Spadea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo De Fabritiis, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo De Fabritiis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica dell'Universita di Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Foa, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Foa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Di Ematologia - Universita Di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Fozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano D'Ardia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Santa Maria della Misericordia&quot; di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Candoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Clinics</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laimonas Griskevicius, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marloes Cuijpers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier De Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E. Posthuma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unversity Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerwin Huls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden-Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8901 BR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mels Hoogendoorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marjolein van der Poel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Walter Van der Velden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susan de Jonge-Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - locatie Leyweg</name>
      <address>
        <city>The Hague</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Danielle van Lammeren - Venema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Escolar Soa Joao</name>
      <address>
        <city>Porto</city>
        <zip>PT 4200 - 319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose E. Guimaraes</last_name>
    </contact>
    <investigator>
      <last_name>Jose E. Guimaraes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly diagnosed</keyword>
  <keyword>AML</keyword>
  <keyword>Elderly</keyword>
  <keyword>Decitabine</keyword>
  <keyword>Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

